Interpretation of the group standard of Guideline for the Workflow of Clinical Comprehensive Evaluation of Drugs
- VernacularTitle:《药品临床综合评价工作流程指南》团体标准解读
- Author:
Rong DUAN
1
;
Zhengxiang LI
2
Author Information
1. Pharmacy Center，Tianjin Medical University General Hospital，Tianjin 300052，China;Tianjin Center for Drug Utilization Monitoring and Clinical Comprehensive Evaluation，Tianjin 300052，China
2. Pharmacy Center，Tianjin Medical University General Hospital，Tianjin 300052，China
- Publication Type:Journal Article
- Keywords:
clinical comprehensive evaluation of drugs;
guideline for the workflow;
group standard;
interpretation
- From:
China Pharmacy
2025;36(23):2893-2898
- CountryChina
- Language:Chinese
-
Abstract:
In order to standardize the workflow for the clinical comprehensive evaluation of drugs， enhance the assessment of research evidence， and improve the application value of research outcomes in translational practice， the Chinese Pharmaceutical Association issued the Guideline for the Workflow of Clinical Comprehensive Evaluation of Drugs （T/CLPA 5-2025） in June 2025. The core points include clarifying the concept of clinical comprehensive evaluation of drugs and standardizing the main work processes and technical essentials. This article provides a detailed interpretation of the technical methods for standard formulation， the operational logic of the four core processes （theme selection， evaluation implementation， evidence evaluation， result application transformation）， and the key points of core technologies. The aim is to assist medical institution technicians， policymakers and researchers in accurately grasping the connotation of the standards， resolving practical concerns such as process connection and technology application， and enhancing the quality and homogenization of evaluation work. It provides support for the scientific decision-making of healthcare and health， and the rational clinical medication.
